Merck and partner Ridgeback Biotherapeutics said on Friday six lab studies showed that their experimental oral COVID-19 drug, molnupiravir, was active against the Omicron variant.
Merck's COVID-19 pill effective against Omicron in lab studies
By REUTERS
03/05/2025 12:46 AM
By REUTERS
03/04/2025 11:21 PM
By REUTERS
03/04/2025 11:17 PM
By REUTERS
03/04/2025 11:12 PM
By REUTERS
03/04/2025 10:46 PM
By REUTERS
03/04/2025 09:27 PM
By REUTERS
03/04/2025 08:30 PM
By REUTERS
03/04/2025 05:41 PM
By REUTERS
03/04/2025 05:24 PM
By REUTERS
03/04/2025 04:45 PM
By REUTERS
03/04/2025 04:44 PM
By REUTERS
03/04/2025 02:47 PM